Phase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 6
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the sixth newsletter from the site. This week it will be more about preclinical than clinical research, but there are still good news! We also have a podcast if you prefer to listen to the newsletter, you can find […]
Phase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/in Clinical Trial, Metastatic, Phase 3/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/in Preclinical Research/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxNew Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/in Observational, Post-hoc/by MaxMistery Solved: How Diabetes Drug Metformin Lowers Blood Sugar by Targeting Cell’s Powerhouse
/in Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026